Xie Liangzhi

Xie Liangzhi is the chairman of Sinocelltech Group, a Beijing-based biological product supplier.

Xie also holds a doctorate in chemical engineering from the Massachusetts Institute of Technology. He worked as a senior engineer at Merck & Co. in the United States from 1997 until 2002. He was in charge of three vaccines' development and production technologies (Varivax®, Proquad®, and Zostavax®). For the adenovirus vector AIDS vaccine, he built globally advanced production technology. The technology is a way of producing the greatest number of cells and viruses for use in a human live virus vaccine. It has achieved cGMP production at scales of 2000L and even 15000L, according to process certification.

After spending 12 years in the United States, Xie returned to China in 2002 to start a business. Sino Biological Inc, a biomedical high-tech firm situated in Beijing's Economic and Technological Development Zone, is led by him. The labs and offices are almost 3,000 square meters in size, and 100 scientists work on animal cell expression biotechnology product research and development.

Estimated Net Worth $3.2 Billion